PDB Short entry for 2VH6 HEADER HYDROLASE 19-NOV-07 2VH6 TITLE STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: TITLE 2 PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS COMPND MOL_ID: 1; COMPND 2 MOLECULE: ACTIVATED FACTOR XA HEAVY CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: ACTIVATED DESGLA, RESIDUES 235-488; COMPND 5 SYNONYM: STUART FACTOR, STUART-PROWER FACTOR; COMPND 6 EC: 3.4.21.6; COMPND 7 OTHER_DETAILS: DISULPHIDE LINKED TO OTHER CHAIN; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: ACTIVATED FACTOR XA LIGHT CHAIN; COMPND 10 CHAIN: B; COMPND 11 FRAGMENT: ACTIVATED DESGLA, RESIDUES 46-179; COMPND 12 SYNONYM: STUART FACTOR, STUART-PROWER FACTOR; COMPND 13 EC: 3.4.21.6; COMPND 14 OTHER_DETAILS: DISULPHIDE LINKED TO OTHER CHAIN SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 OTHER_DETAILS: PURCHASED FROM ENZYME RESEARCH LABS. ISOLATED FROM SOURCE 6 HUMAN BLOOD; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 9 ORGANISM_COMMON: HUMAN; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 OTHER_DETAILS: PURCHASED FROM ENZYME RESEARCH LABS. ISOLATED FROM SOURCE 12 HUMAN BLOOD KEYWDS SERINE PROTEASE, EGF-LIKE DOMAIN, BLOOD COAGULATION, POLYMORPHISM, KEYWDS 2 GLYCOPROTEIN, HYDROXYLATION, GAMMA-CARBOXYGLUTAMIC ACID, CALCIUM, KEYWDS 3 ZYMOGEN, COMPLEX, PROTEASE, HYDROLASE, CLEAVAGE ON PAIR OF BASIC KEYWDS 4 RESIDUES EXPDTA X-RAY DIFFRACTION AUTHOR R.J.YOUNG,A.D.BORTHWICK,D.BROWN,C.L.BURNS-KURTIS,M.CAMPBELL,C.CHAN, AUTHOR 2 M.CHARBAUT,C.W.CHUNG,M.A.CONVERY,H.A.KELLY,N.P.KING,S.KLEANTHOUS, AUTHOR 3 A.M.MASON,A.J.PATEMAN,A.N.PATIKIS,I.L.PINTO,D.R.POLLARD,S.SENGER, AUTHOR 4 G.P.SHAH,J.R.TOOMEY,N.S.WATSON,H.E.WESTON REVDAT 3 08-MAY-19 2VH6 1 REMARK REVDAT 2 03-FEB-09 2VH6 1 JRNL REVDAT 1 16-DEC-08 2VH6 0 JRNL AUTH R.J.YOUNG,A.D.BORTHWICK,D.BROWN,C.L.BURNS-KURTIS,M.CAMPBELL, JRNL AUTH 2 C.CHAN,M.CHARBAUT,C.W.CHUNG,M.A.CONVERY,H.A.KELLY, JRNL AUTH 3 N.PAUL KING,S.KLEANTHOUS,A.M.MASON,A.J.PATEMAN,A.N.PATIKIS, JRNL AUTH 4 I.L.PINTO,D.R.POLLARD,S.SENGER,G.P.SHAH,J.R.TOOMEY, JRNL AUTH 5 N.S.WATSON,H.E.WESTON JRNL TITL STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: JRNL TITL 2 PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS. JRNL REF BIOORG.MED.CHEM.LETT. V. 18 23 2008 JRNL REFN ISSN 0960-894X JRNL PMID 18054228 JRNL DOI 10.1016/J.BMCL.2007.11.023 REMARK 2 REMARK 2 RESOLUTION. 1.95 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.3.0006 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.95 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 21412 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.199 REMARK 3 R VALUE (WORKING SET) : 0.197 REMARK 3 FREE R VALUE : 0.242 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1159 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.95 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.00 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1114 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2610 REMARK 3 BIN FREE R VALUE SET COUNT : 63 REMARK 3 BIN FREE R VALUE : 0.3080 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2227 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 171 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 36.99 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.14000 REMARK 3 B22 (A**2) : -1.84000 REMARK 3 B33 (A**2) : 0.70000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.178 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.162 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.121 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 4.243 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.954 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.931 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2316 ; 0.014 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3133 ; 1.625 ; 1.963 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 283 ; 3.948 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 106 ;27.106 ;24.057 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 392 ;12.069 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 15 ;21.075 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 333 ; 0.111 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 1754 ; 0.006 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 1019 ; 0.203 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1565 ; 0.309 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 183 ; 0.189 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 23 ; 0.186 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 24 ; 0.210 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1456 ; 1.721 ; 2.000 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2262 ; 2.936 ; 4.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 998 ; 3.716 ; 5.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 871 ; 5.457 ; 7.000 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2VH6 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 19-NOV-07. REMARK 100 THE DEPOSITION ID IS D_1290034452. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 24-JAN-02 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.85 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX14.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.96 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 22951 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.930 REMARK 200 RESOLUTION RANGE LOW (A) : 25.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 93.1 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.05000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.95 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.02 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.45000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: REFMAC REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 32.62 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.83 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CRYSTALLISATION WAS CARRIED OUT USING REMARK 280 THE HANGING DROP VAPOUR DIFFUSION METHOD IN 2UL DROPS CONTAINING REMARK 280 A 1:1 MIXTURE OF PROTEIN AND WELL SOLUTION. WELL SOLUTION REMARK 280 CONTAINED 16-20% PEG 6K, 50MM MES-NAOH (PH5.7-6.0), 5MM CACL2 REMARK 280 AND 50MM NACL, PH 5.85, VAPOR DIFFUSION, HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 27.97950 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.48800 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.15450 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.48800 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 27.97950 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.15450 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 TOTAL BURIED SURFACE AREA: 2030 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 16190 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -12.5 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLU A 77 REMARK 465 GLY A 78 REMARK 465 ARG A 245 REMARK 465 GLY A 246 REMARK 465 LEU A 247 REMARK 465 PRO A 248 REMARK 465 LYS A 249 REMARK 465 ALA A 250 REMARK 465 LYS A 251 REMARK 465 SER A 252 REMARK 465 HIS A 253 REMARK 465 ALA A 254 REMARK 465 PRO A 255 REMARK 465 GLU A 256 REMARK 465 VAL A 257 REMARK 465 ILE A 258 REMARK 465 THR A 259 REMARK 465 SER A 260 REMARK 465 SER A 261 REMARK 465 PRO A 262 REMARK 465 LEU A 263 REMARK 465 LYS A 264 REMARK 465 GLU B -82 REMARK 465 GLU B -81 REMARK 465 MET B -80 REMARK 465 LYS B -79 REMARK 465 LYS B -78 REMARK 465 GLY B -77 REMARK 465 HIS B -76 REMARK 465 LEU B -75 REMARK 465 GLU B -74 REMARK 465 ARG B -73 REMARK 465 GLU B -72 REMARK 465 CYS B -71 REMARK 465 MET B -70 REMARK 465 GLU B -69 REMARK 465 GLU B -68 REMARK 465 THR B -67 REMARK 465 CYS B -66 REMARK 465 SER B -65 REMARK 465 TYR B -64 REMARK 465 GLU B -63 REMARK 465 GLU B -62 REMARK 465 ALA B -61 REMARK 465 ARG B -60 REMARK 465 GLU B -59 REMARK 465 VAL B -58 REMARK 465 PHE B -57 REMARK 465 GLU B -56 REMARK 465 ASP B -55 REMARK 465 SER B -54 REMARK 465 ASP B -53 REMARK 465 LYS B -52 REMARK 465 THR B -51 REMARK 465 ASN B -50 REMARK 465 GLU B -49 REMARK 465 PHE B -48 REMARK 465 TRP B -47 REMARK 465 ASN B -46 REMARK 465 LYS B -45 REMARK 465 TYR B -44 REMARK 465 LYS B -43 REMARK 465 ASP B -42 REMARK 465 GLY B -41 REMARK 465 ASP B -40 REMARK 465 GLN B -39 REMARK 465 CYS B -38 REMARK 465 GLU B -37 REMARK 465 THR B -36 REMARK 465 SER B -35 REMARK 465 PRO B -34 REMARK 465 CYS B -33 REMARK 465 GLN B -32 REMARK 465 ASN B -31 REMARK 465 GLN B -30 REMARK 465 GLY B -29 REMARK 465 LYS B -28 REMARK 465 CYS B -27 REMARK 465 LYS B -26 REMARK 465 ASP B -25 REMARK 465 GLY B -24 REMARK 465 LEU B -23 REMARK 465 GLY B -22 REMARK 465 GLU B -21 REMARK 465 TYR B -20 REMARK 465 THR B -19 REMARK 465 CYS B -18 REMARK 465 THR B -17 REMARK 465 CYS B -16 REMARK 465 LEU B -15 REMARK 465 GLU B -14 REMARK 465 GLY B -13 REMARK 465 PHE B -12 REMARK 465 GLU B -11 REMARK 465 GLY B -10 REMARK 465 LYS B -9 REMARK 465 ASN B -8 REMARK 465 CYS B -7 REMARK 465 GLU B -6 REMARK 465 LEU B -5 REMARK 465 PHE B -4 REMARK 465 ARG B 51 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 THR A 244 OG1 CG2 REMARK 470 THR B -3 OG1 CG2 REMARK 470 ARG B -2 CG CD NE CZ NH1 NH2 REMARK 470 LYS B -1 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2106 O HOH B 2011 2.17 REMARK 500 O ASN A 72 O HOH A 2023 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 48 -179.24 -170.48 REMARK 500 ALA A 61A 153.91 178.47 REMARK 500 LYS A 62 -79.25 -84.27 REMARK 500 GLN A 75 -159.42 -117.28 REMARK 500 ARG A 115 -168.31 -166.46 REMARK 500 LEU B 0 -121.52 41.01 REMARK 500 GLN B 10 -115.55 -132.30 REMARK 500 LYS B 34 -48.18 -133.69 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 PRO A 198 HIS A 199 147.47 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 GLY A 223A 10.80 REMARK 500 REMARK 500 REMARK: NULL REMARK 700 REMARK 700 SHEET REMARK 700 DETERMINATION METHOD: DSSP REMARK 700 THE SHEETS PRESENTED AS "AA" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 8-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 9-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 700 THE SHEETS PRESENTED AS "AB" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 7-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 8-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GSV A1245 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2J34 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1WU1 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 4 -[(5-CHLOROINDOL-2-YL) REMARK 900 SULFONYL]-2-(2- METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN -2-YL] REMARK 900 CARBONYL]PIPERAZINE REMARK 900 RELATED ID: 2BQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43 REMARK 900 RELATED ID: 1IOE RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55532 REMARK 900 RELATED ID: 1F0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208707 REMARK 900 RELATED ID: 1NFW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR209685 REMARK 900 RELATED ID: 1XKA RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'- REMARK 900 AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 2GD4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA- REMARK 900 PENTASACCHARIDE COMPLEX REMARK 900 RELATED ID: 1F0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208815 REMARK 900 RELATED ID: 1MSX RELATED DB: PDB REMARK 900 HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N- AMINO-15N-IMINO-13C- REMARK 900 METHYL)PHENOXY]-6-[3 -(15N-AMINO-13C-METHYL)PHENOXY]-3,5- DIFLUORO- REMARK 900 4-METHYLPYRIDINE (ZK-806299), BINDING MODELFROM DOUBLE REDOR NMR REMARK 900 AND MD SIMULATIONS. REMARK 900 RELATED ID: 1LPG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79. REMARK 900 RELATED ID: 1P0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEXWITH REMARK 900 ECOTIN M84R REMARK 900 RELATED ID: 2G00 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 3 -(6-(2'-((DIMETHYLAMINO) REMARK 900 METHYL)-4-BIPHENYLYL )-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7- REMARK 900 TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1- YL)BENZAMIDE REMARK 900 RELATED ID: 2BMG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50 REMARK 900 RELATED ID: 1MQ5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(4-CHLOROPHENYL) REMARK 900 AMINO]CARBONYL]PHENYL]- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2- REMARK 900 THIOPHENECARBOXAMIDE COMPLEXED WITHHUMAN FACTOR XA REMARK 900 RELATED ID: 1IQN RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55192 REMARK 900 RELATED ID: 1MQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(5-CHLORO-2- REMARK 900 PYRIDINYL)AMINO]CARBONYL ]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2- REMARK 900 OXAZOLYL)METHYLAMINO]METHYL]-2- THIOPHENECARBOXAMIDE COMPLEXED WITH REMARK 900 HUMAN FACTOR XA REMARK 900 RELATED ID: 1XKB RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'- REMARK 900 AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 2BQW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45 REMARK 900 RELATED ID: 1IQM RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54471 REMARK 900 RELATED ID: 1EZQ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR128515 REMARK 900 RELATED ID: 1IQE RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55590 REMARK 900 RELATED ID: 1G2M RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1FJS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031)COMPLEXED REMARK 900 WITH FACTOR XA REMARK 900 RELATED ID: 2VH0 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS:BIARYL REMARK 900 PYRROLIDIN-2- ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS REMARK 900 RELATED ID: 1LPK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125. REMARK 900 RELATED ID: 2J4I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1NFY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR200095 REMARK 900 RELATED ID: 2UWL RELATED DB: PDB REMARK 900 SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND REMARK 900 FACTOR XA REMARK 900 RELATED ID: 2BOK RELATED DB: PDB REMARK 900 FACTOR XA - CATION REMARK 900 RELATED ID: 1NFX RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR208944 REMARK 900 RELATED ID: 1LPZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41. REMARK 900 RELATED ID: 1HCG RELATED DB: PDB REMARK 900 BLOOD COAGULATION FACTOR XA REMARK 900 RELATED ID: 2J94 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1IQJ RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55124 REMARK 900 RELATED ID: 1Z6E RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA COMPLEXED TO RAZAXABAN REMARK 900 RELATED ID: 2UWP RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J95 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2CJI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J38 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2BOH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 1 REMARK 900 RELATED ID: 1G2L RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1NFU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR132747 REMARK 900 RELATED ID: 1IQI RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55125 REMARK 900 RELATED ID: 2BQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21 REMARK 900 RELATED ID: 1FAX RELATED DB: PDB REMARK 900 COAGULATION FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1IQF RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55165 REMARK 900 RELATED ID: 1NL8 RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF THE TISSUE FACTOR/ FACTOR VIIA/FACTORXA COMPLEX REMARK 900 RELATED ID: 1KYE RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH (R)-2-(3- ADAMANTAN-1-YL-UREIDO)-3-(3- REMARK 900 CARBAMIMIDOYL- PHENYL)-N-PHENETHYL-PROPIONAMIDE REMARK 900 RELATED ID: 1IQG RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55159 REMARK 900 RELATED ID: 1IQK RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55113 REMARK 900 RELATED ID: 1IQH RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55143 REMARK 900 RELATED ID: 1V3X RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -[6-METHYL-4,5,6,7- REMARK 900 TETRAHYDROTHIAZOLO(5, 4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4 -(6- REMARK 900 CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE REMARK 900 RELATED ID: 1LQD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45. REMARK 900 RELATED ID: 2FZZ RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -(3-AMINO-1,2- REMARK 900 BENZISOXAZOL-5-YL)-6-(2 '-(((3R)-3-HYDROXY-1-PYRROLIDINYL)METHYL)-4 REMARK 900 -BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6- TETRAHYDRO-7H-PYRAZOLO[3, REMARK 900 4-C]PYRIDIN-7- ONE REMARK 900 RELATED ID: 2J2U RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2UWO RELATED DB: PDB REMARK 900 SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND REMARK 900 FACTOR XA REMARK 900 RELATED ID: 1KSN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 FXV673 REMARK 900 RELATED ID: 1C5M RELATED DB: PDB REMARK 900 STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, REMARK 900 SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR REMARK 900 RELATED ID: 1IQL RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54476 REMARK 999 REMARK 999 SEQUENCE REMARK 999 SOME RESIDUES IN CHAIN ARE NOT SEEN IN THE ELECTRON REMARK 999 DENSITY. SEQUENCE DATABASE RESIDUES 1-45 (THE GLA DOMAIN) REMARK 999 WERE BIOCHEMICALLY REMOVED IN CHAIN B DBREF 2VH6 A 16 264 UNP P00742 FA10_HUMAN 235 488 DBREF 2VH6 B -82 49 UNP P00742 FA10_HUMAN 46 179 SEQRES 1 A 254 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 A 254 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 A 254 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 A 254 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 A 254 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 A 254 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 A 254 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 A 254 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 A 254 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 A 254 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 A 254 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 A 254 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 A 254 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 A 254 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 A 254 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 A 254 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 A 254 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 A 254 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS THR SEQRES 19 A 254 ARG GLY LEU PRO LYS ALA LYS SER HIS ALA PRO GLU VAL SEQRES 20 A 254 ILE THR SER SER PRO LEU LYS SEQRES 1 B 134 GLU GLU MET LYS LYS GLY HIS LEU GLU ARG GLU CYS MET SEQRES 2 B 134 GLU GLU THR CYS SER TYR GLU GLU ALA ARG GLU VAL PHE SEQRES 3 B 134 GLU ASP SER ASP LYS THR ASN GLU PHE TRP ASN LYS TYR SEQRES 4 B 134 LYS ASP GLY ASP GLN CYS GLU THR SER PRO CYS GLN ASN SEQRES 5 B 134 GLN GLY LYS CYS LYS ASP GLY LEU GLY GLU TYR THR CYS SEQRES 6 B 134 THR CYS LEU GLU GLY PHE GLU GLY LYS ASN CYS GLU LEU SEQRES 7 B 134 PHE THR ARG LYS LEU CYS SER LEU ASP ASN GLY ASP CYS SEQRES 8 B 134 ASP GLN PHE CYS HIS GLU GLU GLN ASN SER VAL VAL CYS SEQRES 9 B 134 SER CYS ALA ARG GLY TYR THR LEU ALA ASP ASN GLY LYS SEQRES 10 B 134 ALA CYS ILE PRO THR GLY PRO TYR PRO CYS GLY LYS GLN SEQRES 11 B 134 THR LEU GLU ARG HET GSV A1245 35 HETNAM GSV 2-(5-CHLOROTHIOPHEN-2-YL)-N-{(3S)-1-[3-FLUORO-2'- HETNAM 2 GSV (METHYLSULFONYL)BIPHENYL-4-YL]-2-OXOPYRROLIDIN-3- HETNAM 3 GSV YL}ETHANESULFONAMIDE FORMUL 3 GSV C23 H22 CL F N2 O5 S3 FORMUL 4 HOH *171(H2 O) HELIX 1 1 ALA A 55 GLN A 61 5 7 HELIX 2 2 GLU A 124A LEU A 131A 1 9 HELIX 3 3 ASP A 164 SER A 172 1 9 HELIX 4 4 PHE A 234 THR A 244 1 11 HELIX 5 5 LEU B 3 CYS B 8 5 6 SHEET 1 AA 9 GLN A 20 GLU A 21 0 SHEET 2 AA 9 LYS A 156 VAL A 163 -1 O MET A 157 N GLN A 20 SHEET 3 AA 9 MET A 180 ALA A 183 -1 O CYS A 182 N VAL A 163 SHEET 4 AA 9 GLY A 226 LYS A 230 -1 O GLY A 226 N ALA A 183 SHEET 5 AA 9 THR A 206 TRP A 215 -1 O ILE A 212 N THR A 229 SHEET 6 AA 9 PRO A 198 PHE A 203 -1 O HIS A 199 N THR A 210 SHEET 7 AA 9 THR A 135 GLY A 140 -1 O ILE A 137 N VAL A 200 SHEET 8 AA 9 LYS A 156 VAL A 163 1 O LYS A 156 N GLY A 140 SHEET 9 AA 9 GLN A 20 GLU A 21 -1 O GLN A 20 N MET A 157 SHEET 1 AB 8 GLN A 30 ASN A 35 0 SHEET 2 AB 8 GLY A 40 ILE A 46 -1 N PHE A 41 O LEU A 33 SHEET 3 AB 8 TYR A 51 THR A 54 -1 O LEU A 53 N THR A 45 SHEET 4 AB 8 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 5 AB 8 ALA A 81 LYS A 90 -1 N GLU A 86 O ARG A 107 SHEET 6 AB 8 PHE A 64 VAL A 68 -1 O PHE A 64 N VAL A 85 SHEET 7 AB 8 GLN A 30 ASN A 35 -1 O LEU A 32 N ARG A 67 SHEET 8 AB 8 GLN A 30 ASN A 35 0 SHEET 1 BA 2 PHE B 11 GLU B 15 0 SHEET 2 BA 2 SER B 18 SER B 22 -1 O SER B 18 N GLU B 15 SHEET 1 BB 2 TYR B 27 LEU B 29 0 SHEET 2 BB 2 CYS B 36 PRO B 38 -1 O ILE B 37 N THR B 28 SSBOND 1 CYS A 22 CYS A 27 1555 1555 2.02 SSBOND 2 CYS A 42 CYS A 58 1555 1555 2.05 SSBOND 3 CYS A 122 CYS B 44 1555 1555 2.04 SSBOND 4 CYS A 168 CYS A 182 1555 1555 1.96 SSBOND 5 CYS A 191 CYS A 220 1555 1555 2.03 SSBOND 6 CYS B 1 CYS B 12 1555 1555 2.05 SSBOND 7 CYS B 8 CYS B 21 1555 1555 1.99 SSBOND 8 CYS B 23 CYS B 36 1555 1555 2.02 SITE 1 AC1 16 LYS A 96 GLU A 97 THR A 98 TYR A 99 SITE 2 AC1 16 PHE A 174 ASP A 189 ALA A 190 GLN A 192 SITE 3 AC1 16 VAL A 213 TRP A 215 GLY A 216 GLY A 219 SITE 4 AC1 16 GLY A 226 ILE A 227 TYR A 228 HOH A2109 CRYST1 55.959 72.309 78.976 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017870 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013830 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012662 0.00000